Ignore the FDA and buy Acrux, page-26

every 'expert opinion' is subjective - including govt fund trials. a govt funded study said the NBN would deliver large benefit at acceptable cost. Now another one tells us the opposite.

the real issue for Acrux longer term is whether the testosterone market will remain in place post the govt review.

short term - the stock appears within 5% or so of a bottom based on technicals - slow stochastic, commodity channel index and MACD also show stock as significantly oversold and already boucing from a technical low. (not the same thing as share price)

i imagine USD strength may support stock against the naturally weak holders whove seen a lot of volatility.

but it will take some improvement in risk appaetite for te stock to start reclaiming lost ground.